JP2016510028A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016510028A5 JP2016510028A5 JP2015560283A JP2015560283A JP2016510028A5 JP 2016510028 A5 JP2016510028 A5 JP 2016510028A5 JP 2015560283 A JP2015560283 A JP 2015560283A JP 2015560283 A JP2015560283 A JP 2015560283A JP 2016510028 A5 JP2016510028 A5 JP 2016510028A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- cancer
- composition according
- leukemia
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 16
- 206010028980 Neoplasm Diseases 0.000 claims 12
- 201000011510 cancer Diseases 0.000 claims 10
- 150000001875 compounds Chemical class 0.000 claims 4
- 206010039491 Sarcoma Diseases 0.000 claims 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 2
- 208000032612 Glial tumor Diseases 0.000 claims 2
- 206010018338 Glioma Diseases 0.000 claims 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims 2
- 201000005787 hematologic cancer Diseases 0.000 claims 2
- 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 claims 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 201000008968 osteosarcoma Diseases 0.000 claims 2
- 238000001959 radiotherapy Methods 0.000 claims 2
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 claims 1
- 206010003571 Astrocytoma Diseases 0.000 claims 1
- 208000003950 B-cell lymphoma Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 201000008808 Fibrosarcoma Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010025538 Malignant ascites Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 201000010208 Seminoma Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 206010042971 T-cell lymphoma Diseases 0.000 claims 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 201000006083 Xeroderma Pigmentosum Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 210000003679 cervix uteri Anatomy 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- 210000000232 gallbladder Anatomy 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 201000008806 mesenchymal cell neoplasm Diseases 0.000 claims 1
- 208000007538 neurilemmoma Diseases 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 210000001428 peripheral nervous system Anatomy 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 210000000664 rectum Anatomy 0.000 claims 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 206010039667 schwannoma Diseases 0.000 claims 1
- 210000004872 soft tissue Anatomy 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 208000001608 teratocarcinoma Diseases 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 208000030901 thyroid gland follicular carcinoma Diseases 0.000 claims 1
- 210000003932 urinary bladder Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361770901P | 2013-02-28 | 2013-02-28 | |
| US61/770,901 | 2013-02-28 | ||
| PCT/US2014/018759 WO2014134201A1 (en) | 2013-02-28 | 2014-02-26 | A benzoic acid derivative mdm2 inhibitor for the treatment of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016510028A JP2016510028A (ja) | 2016-04-04 |
| JP2016510028A5 true JP2016510028A5 (cg-RX-API-DMAC10.html) | 2017-02-23 |
| JP6266659B2 JP6266659B2 (ja) | 2018-01-24 |
Family
ID=50272765
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015560283A Active JP6266659B2 (ja) | 2013-02-28 | 2014-02-26 | 癌の治療のための安息香酸誘導体ｍｄｍ２阻害剤 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US8952036B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP2961735B1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP6266659B2 (cg-RX-API-DMAC10.html) |
| CN (1) | CN105121407B (cg-RX-API-DMAC10.html) |
| AR (1) | AR094970A1 (cg-RX-API-DMAC10.html) |
| AU (1) | AU2014223547B2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA2902856C (cg-RX-API-DMAC10.html) |
| MX (1) | MX368703B (cg-RX-API-DMAC10.html) |
| TW (1) | TW201505630A (cg-RX-API-DMAC10.html) |
| UY (1) | UY35353A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2014134201A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2118123T3 (en) | 2007-01-31 | 2016-01-25 | Dana Farber Cancer Inst Inc | Stabilized p53 peptides and uses thereof |
| EP3159352B1 (en) | 2007-03-28 | 2023-08-02 | President and Fellows of Harvard College | Stitched polypeptides |
| JO2998B1 (ar) | 2010-06-04 | 2016-09-05 | Amgen Inc | مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان |
| JP6093770B2 (ja) | 2011-09-27 | 2017-03-08 | アムジエン・インコーポレーテツド | 癌の治療のためのｍｄｍ２阻害剤としての複素環化合物 |
| EP2768518A4 (en) | 2011-10-18 | 2015-05-27 | Aileron Therapeutics Inc | PEPTIDOMIMETIC MACROCYCLES |
| WO2013123267A1 (en) | 2012-02-15 | 2013-08-22 | Aileron Therapeutics, Inc. | Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles |
| US8927500B2 (en) | 2012-02-15 | 2015-01-06 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
| US11407721B2 (en) | 2013-02-19 | 2022-08-09 | Amgen Inc. | CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer |
| WO2014138429A2 (en) | 2013-03-06 | 2014-09-12 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and use thereof in regulating hif1alpha |
| MX374513B (es) | 2013-03-14 | 2025-03-06 | Amgen Inc | Compuestos de morfolinona de ácido heteroarilo como inhibidores mdm2 para el tratamiento de cáncer. |
| JOP20200296A1 (ar) | 2013-06-10 | 2017-06-16 | Amgen Inc | عمليات صنع وأشكال بلورية من mdm2 مثبط |
| GB201311888D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201311891D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| NZ758548A (en) | 2013-11-11 | 2022-02-25 | Amgen Inc | Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers |
| US20180228907A1 (en) | 2014-04-14 | 2018-08-16 | Arvinas, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| MX2017003797A (es) | 2014-09-24 | 2017-06-15 | Aileron Therapeutics Inc | Macrociclos peptidomimeticos y usos de los mismos. |
| US12312316B2 (en) | 2015-01-20 | 2025-05-27 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| WO2016118666A1 (en) | 2015-01-20 | 2016-07-28 | Arvinas, Inc. | Compounds and methods for the targeted degradation of the androgen receptor |
| CN107614003A (zh) | 2015-03-20 | 2018-01-19 | 艾瑞朗医疗公司 | 拟肽大环化合物及其用途 |
| WO2016197114A1 (en) | 2015-06-05 | 2016-12-08 | Arvinas, Inc. | Tank-binding kinase-1 protacs and associated methods of use |
| WO2017030814A1 (en) | 2015-08-19 | 2017-02-23 | Arvinas, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
| US9962380B2 (en) * | 2015-09-23 | 2018-05-08 | Wisconsin Alumni Research Foundation | Methods for treating cognitive deficits associated with fragile X syndrome |
| JP7037500B2 (ja) * | 2016-04-06 | 2022-03-16 | ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン | Ｍｄｍ２タンパク質分解剤 |
| KR20180132861A (ko) * | 2016-04-12 | 2018-12-12 | 더 리젠츠 오브 더 유니버시티 오브 미시간 | Bet 단백질 분해제 |
| KR102570992B1 (ko) | 2016-11-01 | 2023-08-28 | 아비나스 오퍼레이션스, 인코포레이티드 | 타우(Tau)-단백질 표적화 프로탁(PROTAC) 및 관련 사용 방법 |
| CN110291087B (zh) | 2016-12-01 | 2024-07-09 | 阿尔维纳斯运营股份有限公司 | 作为雌激素受体降解剂的四氢萘和四氢异喹啉衍生物 |
| WO2018119441A1 (en) | 2016-12-23 | 2018-06-28 | Arvinas, Inc. | Egfr proteolysis targeting chimeric molecules and associated methods of use |
| US11173211B2 (en) | 2016-12-23 | 2021-11-16 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides |
| US10723717B2 (en) | 2016-12-23 | 2020-07-28 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides |
| EP3559006A4 (en) | 2016-12-23 | 2021-03-03 | Arvinas Operations, Inc. | COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF F TAL LIVER KINASE POLYPEPTIDES |
| US11191741B2 (en) | 2016-12-24 | 2021-12-07 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide |
| US10604506B2 (en) | 2017-01-26 | 2020-03-31 | Arvinas Operations, Inc. | Modulators of estrogen receptor proteolysis and associated methods of use |
| EP3710443A1 (en) | 2017-11-17 | 2020-09-23 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides |
| CN112218859B (zh) | 2018-04-04 | 2024-10-29 | 阿尔维纳斯运营股份有限公司 | 蛋白水解调节剂及相关使用方法 |
| IL308399B2 (en) * | 2018-04-30 | 2025-08-01 | Kartos Therapeutics Inc | Methods of treating cancer |
| MX2020012503A (es) * | 2018-05-25 | 2021-08-11 | Kartos Therapeutics Inc | Métodos de tratamiento de neoplasias mieloproliferativas. |
| CN112912376A (zh) | 2018-08-20 | 2021-06-04 | 阿尔维纳斯运营股份有限公司 | 用于治疗神经变性疾病的具有E3泛素连接酶结合活性并靶向α-突触核蛋白的蛋白水解靶向嵌合(PROTAC)化合物 |
| CN110963958B (zh) * | 2018-09-30 | 2025-10-10 | 上海长森药业有限公司 | 一种mdm2抑制剂，及其制备方法、药物组合物和应用 |
| KR20220054347A (ko) | 2019-08-26 | 2022-05-02 | 아비나스 오퍼레이션스, 인코포레이티드 | 에스트로겐 수용체 분해제로서의 테트라히드로나프탈렌 유도체로 유방암을 치료하는 방법 |
| WO2022047145A1 (en) | 2020-08-28 | 2022-03-03 | Arvinas Operations, Inc. | Rapidly accelerating fibrosarcoma protein degrading compounds and associated methods of use |
| AR123492A1 (es) | 2020-09-14 | 2022-12-07 | Arvinas Operations Inc | Formas cristalinas y amorfas de un compuesto para la degradación dirigida del receptor de estrógeno |
| WO2024054591A1 (en) | 2022-09-07 | 2024-03-14 | Arvinas Operations, Inc. | Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use |
| IL322247A (en) | 2023-01-26 | 2025-09-01 | Arvinas Operations Inc | Cerebellon-based KRAS-disrupting proteins and related uses |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1016828A (en) | 1961-11-13 | 1966-01-12 | Mcneilab Inc | Substituted morpholines and process for preparing same |
| DE3246148A1 (de) | 1982-12-14 | 1984-06-14 | Troponwerke GmbH & Co KG, 5000 Köln | Pyrazolo(4.3-b)(1.4)oxazine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
| US5334720A (en) | 1991-03-07 | 1994-08-02 | Fisons Corporation | Diphenyl-1-(aminoalkyl)-2-piperidinone and -2-pyrrolidinone derivatives having anticonvulsant properties |
| WO1995023135A1 (en) | 1991-03-07 | 1995-08-31 | Fisons Corporation | Diphenyl-2-piperidinone and -2-pyrrolidinone derivatives having anti-convulsant and neuroprotective activity |
| ES2179881T3 (es) | 1994-08-19 | 2003-02-01 | Abbott Lab | Antagonistas de endotelina. |
| KR100508200B1 (ko) | 1996-02-13 | 2005-12-16 | 아보트 러보러터리즈 | 엔도텔린길항제로서의벤조-1,3-디옥솔릴-및벤조푸라닐치환된피롤리딘유도체및이를함유하는약제 |
| US6159990A (en) | 1997-06-18 | 2000-12-12 | Synaptic Pharmaceutical Corporation | Oxazolidinones as α1A receptor antagonists |
| TR200101233T2 (tr) | 1997-08-04 | 2002-06-21 | Abbott Laboratories | Endotelin antagonistleri. |
| AU1910299A (en) | 1997-12-18 | 1999-07-05 | Eli Lilly And Company | Peptidomimetic template-based combinatorial libraries |
| US6770658B2 (en) | 1998-09-09 | 2004-08-03 | Inflazyme Pharmaceuticals Ltd. | Substituted γ-phenyl-Δ-lactams and uses related thereto |
| WO2002017912A1 (en) | 2000-08-31 | 2002-03-07 | Abbott Laboratories | Endothelin antagonists |
| EP1358178A2 (en) | 2001-01-30 | 2003-11-05 | Bristol-Myers Squibb Company | Sulfonamide lactam inhibitors of factor xa |
| AU2002305450A1 (en) | 2001-05-08 | 2002-11-18 | Yale University | Proteomimetic compounds and methods |
| EP1395560A1 (en) | 2001-05-23 | 2004-03-10 | Ucb, S.A. | 2-oxo-piperidinyl- and 2-oxo-azepanyl alkanoic acid derivativ es for the treatment of epilepsy and other neurological disorders |
| ES2301717T3 (es) | 2001-12-18 | 2008-07-01 | F. Hoffmann-La Roche Ag | Cis-2,4,5-trifenil-imidazolinas y su utilizacion para el tratamiento de tumores. |
| US7425638B2 (en) | 2003-06-17 | 2008-09-16 | Hoffmann-La Roche Inc. | Cis-imidazolines |
| DE602005011132D1 (de) | 2004-05-18 | 2009-01-02 | Hoffmann La Roche | Neuartige cis-imidazoline |
| US7893278B2 (en) | 2004-06-17 | 2011-02-22 | Hoffman-La Roche Inc. | CIS-imidazolines |
| KR20100031783A (ko) | 2005-03-16 | 2010-03-24 | 에프. 호프만-라 로슈 아게 | 시스-２，４，５-트리아릴-이미다졸린 및 항암 약제로서의 그의 용도 |
| HRP20110524T1 (hr) | 2005-04-04 | 2011-08-31 | Eisai R&D Management Co. | Spojevi dihidropiridina za neurodegenerativne bolesti i demenciju |
| JP4870778B2 (ja) | 2005-12-01 | 2012-02-08 | エフ．ホフマン−ラ ロシュ アーゲー | 抗ガン剤として使用されるｐ５３およびｍｄｍ２タンパク質間の相互作用の阻害剤としての２，４，５−トリフェニルイミダゾリン誘導体 |
| US20070213341A1 (en) | 2006-03-13 | 2007-09-13 | Li Chen | Spiroindolinone derivatives |
| MX2009000285A (es) | 2006-06-30 | 2009-06-08 | Schering Corp | Piperidinas sustituidas que incrementan la actividad de p53 y usos de las mismas. |
| US20100092427A1 (en) | 2006-07-19 | 2010-04-15 | The University Of Georgia Research Foundation | Pyridinone Diketo Acids: Inhibitors of HIV Replication in Combination Therapy |
| US7618989B2 (en) | 2006-08-15 | 2009-11-17 | Wyeth | Tricyclic oxazolidone derivatives useful as PR modulators |
| US20080045560A1 (en) | 2006-08-15 | 2008-02-21 | Wyeth | Pyrrolidine and related derivatives useful as PR modulators |
| TW200831080A (en) | 2006-12-15 | 2008-08-01 | Irm Llc | Compounds and compositions as inhibitors of cannabinoid receptor 1 activity |
| GB0722769D0 (en) | 2007-11-21 | 2008-01-02 | Biolipox Ab | New compounds |
| US7625895B2 (en) | 2007-04-12 | 2009-12-01 | Hoffmann-Le Roche Inc. | Diphenyl-dihydro-imidazopyridinones |
| WO2008130614A2 (en) | 2007-04-20 | 2008-10-30 | University Of Pittsburg-Of The Commonwealth System Of Higher Education | Selective and dual-action p53/mdm2/mdm4 antagonists |
| US7834179B2 (en) | 2007-05-23 | 2010-11-16 | Hoffmann-La Roche Inc. | Spiroindolinone derivatives |
| WO2009004430A1 (en) | 2007-06-29 | 2009-01-08 | Pfizer Inc. | N-benzyl oxazolidinones and related heterocycleic compounds as potentiators of glutamate receptors |
| WO2009047161A1 (en) | 2007-10-09 | 2009-04-16 | F. Hoffmann-La Roche Ag | Chiral cis-imidazolines |
| US7776875B2 (en) | 2007-12-19 | 2010-08-17 | Hoffman-La Roche Inc. | Spiroindolinone derivatives |
| US20100256191A1 (en) | 2007-12-26 | 2010-10-07 | Eisai R&D Management Co., Ltd. | Ampa receptor antagonists and zonisamide for epilepsy |
| EP2268616A1 (en) | 2008-03-21 | 2011-01-05 | Chlorion Pharma, Inc. | Substituted pyrrolidine and piperidine compounds, derivatives thereof, and methods for treating pain |
| GB0811643D0 (en) | 2008-06-25 | 2008-07-30 | Cancer Rec Tech Ltd | New therapeutic agents |
| TW201011009A (en) | 2008-09-15 | 2010-03-16 | Priaxon Ag | Novel pyrrolidin-2-ones |
| RU2506257C2 (ru) | 2008-09-18 | 2014-02-10 | Ф.Хоффманн-Ля Рош Аг | Замещенные пирролидин-2-карбоксамиды |
| US8076482B2 (en) | 2009-04-23 | 2011-12-13 | Hoffmann-La Roche Inc. | 3,3′-spiroindolinone derivatives |
| KR20120050492A (ko) | 2009-08-26 | 2012-05-18 | 노파르티스 아게 | 테트라-치환된 헤테로아릴 화합물 및 ｍｄｍ2 및/또는 ｍｄｍ4 조절제로서의 그의 용도 |
| US8088815B2 (en) * | 2009-12-02 | 2012-01-03 | Hoffman-La Roche Inc. | Spiroindolinone pyrrolidines |
| US8440693B2 (en) | 2009-12-22 | 2013-05-14 | Novartis Ag | Substituted isoquinolinones and quinazolinones |
| JO2998B1 (ar) * | 2010-06-04 | 2016-09-05 | Amgen Inc | مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان |
| US20120010235A1 (en) * | 2010-07-12 | 2012-01-12 | Xin-Jie Chu | N-substituted pyrrolidines |
| US20120046306A1 (en) * | 2010-08-18 | 2012-02-23 | David Joseph Bartkovitz | Substituted Heteroaryl Spiropyrrolidine MDM2 Antagonists |
| CN102153557B (zh) | 2011-01-21 | 2013-03-20 | 中国科学院上海有机化学研究所 | 具有乙二胺骨架的多手性中心氮杂环卡宾前体盐、合成方法及用途 |
| JP6093770B2 (ja) | 2011-09-27 | 2017-03-08 | アムジエン・インコーポレーテツド | 癌の治療のためのｍｄｍ２阻害剤としての複素環化合物 |
-
2014
- 2014-02-26 WO PCT/US2014/018759 patent/WO2014134201A1/en not_active Ceased
- 2014-02-26 JP JP2015560283A patent/JP6266659B2/ja active Active
- 2014-02-26 CN CN201480011184.XA patent/CN105121407B/zh active Active
- 2014-02-26 CA CA2902856A patent/CA2902856C/en active Active
- 2014-02-26 MX MX2015011245A patent/MX368703B/es active IP Right Grant
- 2014-02-26 EP EP14709849.5A patent/EP2961735B1/en active Active
- 2014-02-26 AU AU2014223547A patent/AU2014223547B2/en active Active
- 2014-02-27 UY UY0001035353A patent/UY35353A/es not_active Application Discontinuation
- 2014-02-27 US US14/192,553 patent/US8952036B2/en active Active
- 2014-02-27 TW TW103106905A patent/TW201505630A/zh unknown
- 2014-02-28 AR ARP140100685A patent/AR094970A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016510028A5 (cg-RX-API-DMAC10.html) | ||
| JP2012082234A5 (cg-RX-API-DMAC10.html) | ||
| HRP20202065T1 (hr) | Kristalni oblik inhibitora mdm2 | |
| RU2441005C2 (ru) | Новые пиразолопиримидины как ингибиторы циклинзависимых киназ | |
| JP2017517506A5 (cg-RX-API-DMAC10.html) | ||
| PE20221259A1 (es) | Uso del inhibidor de fak en la preparacion de un farmaco para el tratamiento contra tumores con mutacion nras | |
| CL2014001792A1 (es) | Compuestos derivados de carbamato; composicion farmaceutica, y uso de los mismos en el tratamiento del dolor, cancer por tumor solido, obesidad, entre otras enfermedades. | |
| RU2015154275A (ru) | Комбинации антитела против pd-l1 и ингибитора mek и/или ингибитора braf | |
| FI3694529T3 (fi) | Trispesifiset proteiinit ja niiden käyttömenetelmät | |
| HRP20240055T1 (hr) | Derivati piperidinona kao inhibitori mdm2 za liječenje raka | |
| MX419719B (es) | Linfocitos infiltrantes de tumores remanentes y metodos de preparacion y uso de los mismos. | |
| JP2015534578A5 (cg-RX-API-DMAC10.html) | ||
| MX2017012965A (es) | Anticuerpo anti-c-met y conjugado de farmaco citotoxico de anticuerpo anti-c-met y uso farmaceutico del mismo. | |
| JP2016536286A5 (cg-RX-API-DMAC10.html) | ||
| JP2017524735A5 (cg-RX-API-DMAC10.html) | ||
| RU2019114963A (ru) | Дуокармициновые adc, демонстрирующие улучшенную противоопухолевую активность in vivo | |
| JP2015500225A5 (cg-RX-API-DMAC10.html) | ||
| FI3328827T3 (fi) | Glutamiinianalogien aihiolääkkeitä | |
| HRP20220258T1 (hr) | Sastavi 1,2,4-oksadiazola i tiadiazola kao imunomodulatora | |
| JP2019508440A5 (cg-RX-API-DMAC10.html) | ||
| JP2018516917A5 (cg-RX-API-DMAC10.html) | ||
| GEP20237479B (en) | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer | |
| JP2017530983A5 (cg-RX-API-DMAC10.html) | ||
| JP2015511609A5 (cg-RX-API-DMAC10.html) | ||
| LT3806898T (lt) | Gremlin-1 antagonistas, skirtas naudoti vėžio gydymui |